In rat hepatoma cell lines, ezetimibe appears to work by either preventing the interaction between NPC1L1 and cholesterol or by blocking the tunnel of NPC1L1, thereby reducing cholesterol transport (Ge et al., 2008; Huang et al., 2020). Here, NPC1L1 is linked to hepatocellular carcinoma.